Detailed interpretation of the instructions for use of baricitinib/alemin

Baricitinib is a selective Janus kinase (JAK) inhibitor that fundamentally regulates cytokine-mediated inflammatory and immune responses by blocking the JAK-STAT signaling pathway. This pathway plays a central role in a variety of autoimmune diseases and inflammatory reactions, so this drug has been widely studied and applied in the treatment of diseases such as rheumatoid arthritis, COVID-19, and severe alopecia areata.

1. Overview of indications

1. Rheumatoid Arthritis（Rheumatoid Arthritis)

This medicine is indicated for adults with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or moreTNF blockers. By inhibiting JAK1/JAK2 signaling, this product can reduce the release of inflammatory cytokines such as IL-6 and IFN, thereby relieving joint swelling and pain, morning stiffness and synovial inflammation. The drug can be used alone or in combination with methotrexate or other nonbiological DMARDs to enhance its anti-inflammatory effects and delay structural destruction of joints.

2. COVID-19 hospitalization

For adult COVID-19 patients who require hospitalization and receive oxygen therapy, non-invasive or invasive ventilation, or extracorporeal membrane oxygenation (ECMO) support, this drug can help control inflammatory cell storm. Studies show it helps improve respiratory function and shorten hospital stays by modulating immune responses and reducing levels of inflammatory markers. The treatment cycle usually does not exceed 14 days and is designed to quickly control excessive immune responses in the acute phase and reduce the risk of organ damage.

3. Severe alopecia areata (Alopecia Areata)

This product is one of the few systemic drugs that has been proven to improve severe alopecia areata. It blocks abnormal immune signals that attack hair follicles by inhibiting the JAK pathway, thereby restoring hair follicle function and promoting hair regeneration. Indicated for patients with extensive hair loss, loss of eyebrows or eyelashes. Some patients can see significant hair regrowth after a few weeks of treatment, but the efficacy varies between individuals.

Restrictions on use: It is not recommended to use it in combination with otherJAK inhibitors, biologic DMARDs or strong immunosuppressants (such as azathioprine, cyclosporine) to avoid superimposed infection risks or excessive immunosuppression.

2. Recommended dosage and usage

1. Rheumatoid arthritis: The recommended dose is 2 mg taken orally daily, which can be used alone or in combination with methotrexate, etc. The medication time can be fixed and will not be affected by food intake.

2. COVID-19: Take 4 mg orally daily, and the maximum course of treatment is 14 days. The main goals are to reduce the inflammatory response and improve oxygenation status.

3. Severe alopecia areata: The starting dose is 2mg per day, which can be increased to 4mg when the effect is not satisfactory. For patients with almost complete hair loss, treatment is often started with 4mg/day, and can be reduced back to 2mg for maintenance after satisfactory results are achieved.

4. Special groups: Patients with liver function impairment need to adjust the dose as appropriate; elderly patients are recommended to monitor blood routine and liver and kidney function.

3. Common adverse reactions

1. Patients with rheumatoid arthritis: The most common reactions include upper respiratory tract infection, nausea, herpes simplex and herpes zoster. Some patients may have mild transaminase elevations or dyslipidemia.

2. COVID-19 patients: Due to complex underlying conditions, rare complications such as elevated liver enzymes, increased platelets, neutropenia, increased creatine phosphokinase, and venous thrombosis or pulmonary embolism may occur.

3. Patients with alopecia areata: The main symptoms are headache, acne, hyperlipidemia, mild anemia or fatigue, etc. Some patients may also develop folliculitis, slight weight gain, or genital candida infection, which are usually mild to moderate reversible reactions.

4. Usage methods and precautions

This medicine is an oral preparation and can be taken with food or on an empty stomach. There is little difference in absorption rate. The tablets are not biohazardous if taken whole, but for patients with swallowing difficulties, the tablets can be crushed and dispersed in water. The dissolved medicinal solution should be used within 4 hours to ensure efficacy.

If the patient requires medication through a gastrostomy tube, nasogastric tube, or orogastric tube due to disease, dispersible dosage forms can be used for administration. It should be noted that there is insufficient data on whether crushed powder has potential risks to the reproductive system, so medical personnel should take protective measures.

Reference materials:https://go.drugbank.com/drugs/DB11817